Inovio Pharmaceuticals (INO) Corporate presentation summary

Strategic focus and platform overview

• Developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, targeting high unmet needs and market opportunities.

• Proprietary CELLECTRA delivery device enhances DNA medicine uptake, with over 19,000 doses administered in clinical settings.

• DNA medicines platform enables in vivo protein production, inducing cytotoxic T cells and monoclonal antibodies for disease treatment and prevention.

• Platform strengths include versatility, immunogenicity, re-dosing capability, and no need for frozen storage.

• Commercial-scale manufacturing established for plasmids and devices.

Lead program: INO-3107 for recurrent respiratory papillomatosis (RRP)

• BLA accepted by FDA under accelerated approval, with PDUFA target date of October 30, 2026.

• Phase 1/2 trial showed 72% overall response rate at 1 year, improving to 86% at 2 years, with significant reduction in surgeries.

• 28% of patients had no surgeries in year 1, increasing to 50% in year 2; median decrease of 3 surgeries per year.

• Well-tolerated safety profile, with most adverse events being mild and transient.

• Designed to generate antigen-specific T cell response against HPV-6 and -11, addressing the underlying cause of RRP.

Clinical pipeline and late-stage candidates

• Deep pipeline includes candidates for anal and cervical dysplasia, head and neck cancer, glioblastoma, HIV, and Ebola.

• INO-3112 in combination with LOQTORZI targets HPV-related oropharyngeal cancer; Phase 3 trial planned.

• INO-5412 in partnership with Dana-Farber and Akeso for glioblastoma, evaluating combination with cadonilimab.

• VGX-3100 licensed to ApolloBio in China for cervical dysplasia, met primary endpoint in Phase 3 trial.

• Ongoing trials for anal HSIL in both HIV-negative and HIV-positive populations.